Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
G. R. Blumenschein
Consultant or Advisory Role - Bayer
Research Funding - Bayer
J. R. Molina
Research Funding - Bayer
C. D. Lathia
Employment or Leadership Position - Bayer
T. J. Ong
Employment or Leadership Position - Bayer
D. Roth
Employment or Leadership Position - Bayer
P. Rajagopalan
Employment or Leadership Position - Bayer
F. V. Fossella
Research Funding - Bayer
M. S. Kies
Research Funding - Bayer
R. S. Marks
No relevant relationships to disclose
A. A. Adjei
Research Funding - Bayer
P. R. Sundaresan
Employment or Leadership Position - Bayer